Clearmind Medicine will be embarking on a first-in-human clinical trial evaluating the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD).
Biopharmaceutical company, Silo Pharma, has announced plans to study its novel joint homing peptide in the treatment of rheumatoid arthritis.
MAPS has announced further developments in its Phase 3 study of MDMA-assisted therapy for the treatment of PTSD.
A team at the Allen Institute for Brain Science, a division of the Allen Institute, has sent brain samples on a “trip” to gain insights into...
Beckley Psytech has announced the successful completion of its Phase I clinical study of lead candidate BPL-003, a novel benzoate formulation of 5-MeO-DMT.
Cybin’s CYB004-E Phase 1 trial evaluating DMT has completed dosing for four out of five participant cohorts.
Collaborators of Tryp Therapeutics from the University of Michigan will present two scientific posters at the Society for Neuroscience conference.
How do treatments for mood and anxiety disorders derived from psilocybin exert their effects in the brain?
Beckley Psytech has dosed the first participant in its Phase 1 single-ascending dose (SAD) study of ELE-101 – a novel intravenous formulation of psilocin – with...
Apex Labs has been granted approval by Health Canada for the first North American take-home multi-dose psilocybin clinical trial evaluating the safety and efficacy of APEX-52...